Indication for symptomatic VMA
ThromboGenics has announced that the US Food and Drug Administration (FDA) has approved JETREAR (ocriplasmin) in the US for the treatment of symptomatic VMA. Dr Patrik De Haes, CEO of ThromboGenics, said: “The FDA approval of JETREAR is a major milestone for the company. We are extremely pleased that we will be able to meet a major unmet clinical need in ophthalmology when we make JETREAR, the first pharmacological agent for symptomatic VMA, available to the many thousands of US patients who could benefit from treatment of this progressive, sight-threatening condition. We are continuing to prepare for the planned launch of JETREAR in January 2013 through our own US commercial organisation. This is the biggest step in transforming ThromboGenics into a profitable biopharmaceutical company developing and commercialising innovative ophthalmic medicines,†said Dr De Haes. Â
•  www.thrombogenics.comÂ
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.